摘要
目的:探讨加巴喷丁联合西酞普兰对慢性偏头痛(CM)伴广泛性焦虑障碍患者的临床疗效、安全性及两药的有效剂量。方法:按照随机数字表法将210例慢性偏头痛患者纳入加巴喷丁联合西酞普兰组(治疗组)105例和托吡酯联合西酞普兰组(对照组)105例,均治疗6个月。分别记录2组患者治疗前及治疗3,6个月后每月发作天数、偏头痛严重程度视觉模拟评分(VAS)、偏头痛特异性生活质量问卷(MSQ V2.1)、头痛影响测定-6(HIT-6)、匹兹堡睡眠质量指数(PSQI)、汉密尔顿焦虑量表(HAMA)评分和药物不良反应。结果:持续治疗6个月,2组患者头痛发作天数、VAS、HIT-6、PSQI、MSQ V2.1评分均下降,治疗组患者头痛天数下降更显著,对照组患者MSQ V2.1总评分下降更显著(均P<0.05)。2组患者有效率差异无显著性(P>0.05)。加巴喷丁(1.2 g·d^(-1))或者托吡酯(100 mg·d^(-1))联合西酞普兰(10 mg·d^(-1))是理想的治疗CM伴广泛性焦虑障碍的药物剂量。2组药物不良反应发生率均较低(P>0.05)。结论:加巴喷丁(1.2 g·d^(-1))联合西酞普兰(10 mg·d^(-1))能显著减少CM伴广泛性焦虑障碍患者偏头痛发作天数,降低偏头痛患者疼痛程度,改善睡眠,提高生活质量,不良反应小,疗效不劣于托吡酯联合西酞普兰治疗方案。
OBJECTIVE To explore the clinical efficacy and safety of gabapentin plus citalopram in the treatment of chronic migraine(CM)patients with generalized anxiety disorder and determine the effective doses of two drugs.METHODS According to the random number table method,210 CM patients were divided into two groups of gabapentin plus citalopram and topiramate plus citalopram(n=105 each).Attack days,visual analogue scale(VAS),migraine specific quality-of-life questionnaire(MSQ v2.1),headache impact test-6(HIT-6),Pittsburgh sleep quality index(PSQI),Hamilton anxiety scale(HAMA)score and adverse drug reactions were evaluated before and after 3/6 months of treatment.RESULTS After 6-month treatment,headache attack days,VAS,HIT-6,PSQI,MSQ v2.1 scores of two groups decreased,headache days declined more markedly in treatment group and the total score of MSQ v2.1 dropped more markedly in control group(all P<0.05).The effective rate of two groups was similar(P>0.05).Gabapentin(1.2 g·d^(-1))or topiramate(100 mg·d^(-1))plus citalopram(10 mg·d^(-1))was ideal for CM with generalized anxiety disorder.The incidence of adverse drug reactions was lower in both groups(P>0.05).CONCLUSION For CM patients with generalized anxiety disorder,gabapentin(1.2 g·d^(-1))plus citalopram(10 mg·d^(-1))can significantly reduce the duration of migraine attack and lessen the degree of pain,improve sleep,enhance quality-of-life and have fewer adverse reactions.The curative efficacy is not inferior to that of topiramate plus citalopram.
作者
梁军利
唐士婷
梁津瑜
赵丽君
LIANG Jun-li;TANG Shi-ting;LIANG Jin-yu;ZHAO Li-jun(Department of Neurology,the Second Affiliated Hospital,Guangxi Medical University,Guangxi Nanning 530000,China;Department of Neurology,No.923 Hospital of Joint Logistics Support Force of PLA,Guangxi Nanning 530000,China)
出处
《中国医院药学杂志》
CAS
北大核心
2021年第11期1131-1136,共6页
Chinese Journal of Hospital Pharmacy
基金
广西壮族自治区卫生健康委员会自筹经费科研课题(编号:Z20200241)。
关键词
慢性偏头痛
焦虑症
西酞普兰
加巴喷丁
托吡酯
chronic migraine
anxiety disorders
citalopram
gabapentin
topiramate
